Sandra Orozco-Suárez

Dr. Sandra Orozco-Suárez

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
LLLourdes Lorigados
Lourdes Lorigados
LCLilia Morales Chacon
Lilia Morales Chacon
NPNancy Pavón
Nancy Pavón
MRMaria de los Angeles Robinson-Agramonte
Maria de los Angeles Robinson-Agramonte
TSTeresa Serrano Sanchez
Teresa Serrano Sanchez
SOSandra Orozco-Suárez
Sandra Orozco-Suárez
Increasing amounts of evidence support the role of inflammation in epilepsy. This study was done to evaluate serum follow-up of IL-1β and IL-6 levels, as well as their concentration in the neocortex, and the relationship of central inflammation with NF-κB and annexin V in drug-resistant temporal lobe epileptic (DRTLE) patients submitted to surgical treatment. Peripheral and central levels of IL-1β and IL-6were measured by ELISA in 10 DRTLE patients. The sera from patients were taken before surgery, and 12 and 24 months after surgical treatment. The neocortical expression of NF-κB was evaluated by western blotting and annexin V co-localization with synaptophysin by immunohistochemistry. The neocortical tissues from five patients who died by non-neurological causes were used as control. Decreased serum levels of IL-1 and IL-6 were observed after surgery; at this time, 70% of patients were seizure-free. No values of IL-1 and IL-6 were detected in neocortical control tissue, whereas cytokine levels were evidenced in DRTLE. Increased NF-κB neocortex expression was found and the positive annexin V neurons were more obvious in the DRTLE tissue, correlating with IL-6 levels. The follow-up study confirmed that the inflammatory alterations disappeared one year after surgery, when the majority of patients were seizure-free, and the apoptotic death process correlated with inflammation.

12 November 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ACAngélica Coyoy-Salgado
Angélica Coyoy-Salgado
JSJulia Segura-Uribe
Julia Segura-Uribe
CGChristian Guerra-Araiza
Christian Guerra-Araiza
SOSandra Orozco-Suárez
Sandra Orozco-Suárez
HSHermelinda Salgado-Ceballos
Hermelinda Salgado-Ceballos
COCarlos Enrique Orozco-Barrios
Carlos Enrique Orozco-Barrios
Patients with spinal cord injury (SCI) face devastating health, social, and financial consequences, as well as their families and caregivers. Reducing the levels of reactive oxygen species (ROS) and oxidative stress are essential strategies for SCI treatment. Some compounds from traditional medicine could be useful to decrease ROS generated after SCI. This review is aimed at highlighting the importance of some natural compounds with antioxidant capacity used in traditional medicine to treat traumatic SCI. An electronic search of published articles describing animal models of SCI treated with natural compounds from traditional medicine was conducted using the following terms: Spinal Cord Injuries (MeSH terms) AND Models, Animal (MeSH terms) AND [Reactive Oxygen Species (MeSH terms) AND/OR Oxidative Stress (MeSH term)] AND Medicine, Traditional (MeSH terms). Articles reported from 2010 to 2018 were included. The results were further screened by title and abstract for studies performed in rats, mice, and nonhuman primates. The effects of these natural compounds are discussed, including their antioxidant, anti-inflammatory, and antiapoptotic properties. Moreover, the antioxidant properties of natural compounds were emphasized since oxidative stress has a fundamental role in the generation and progression of several pathologies of the nervous system. The use of these compounds diminishes toxic effects due to their high antioxidant capacity. These compounds have been tested in animal models with promising results; however, no clinical studies have been conducted in humans. Further research of these natural compounds is crucial to a better understanding of their effects in patients with SCI.

9 July 2008 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
ADAraceli Diaz-Ruiz
Araceli Diaz-Ruiz
CZCarlos Zavala
Carlos Zavala
SMSergio Montes
Sergio Montes
AOAlma Ortiz‐Plata
Alma Ortiz‐Plata
HSHermelinda Salgado‐Ceballos
Hermelinda Salgado‐Ceballos
CRCamilo Ríos
Camilo Ríos

1 September 2011 in Neuropharmacology
Verified
Journal Article
Closed access
HLHiram Luna-Munguia
Hiram Luna-Munguia
SOSandra Orozco-Suárez
Sandra Orozco-Suárez
LRLuisa Rocha
Luisa Rocha

9 July 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JJJ. M. Dueñas Jiménez
J. M. Dueñas Jiménez
AAA. Candanedo Arellano
A. Candanedo Arellano
ASA. Santerre
A. Santerre
SOSandra Orozco-Suárez
Sandra Orozco-Suárez
HSH. Sandoval Sánchez
H. Sandoval Sánchez
SJS. H. Dueñas Jiménez
S. H. Dueñas Jiménez

14 May 2004 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MCManola Cuéllar‐Herrera
Manola Cuéllar‐Herrera
MVMarcos Velasco
Marcos Velasco
FVFrancisco Velasco
Francisco Velasco
AVAna Luisa Velasco
Ana Luisa Velasco
FJFiacro Jiménez
Fiacro Jiménez
LRLuisa Rocha
Luisa Rocha